Diabetic retinopathy is a leading cause of visual impairment and blindness in developed countries due to macular edema and proliferative diabetic retinopathy (PDR). For both complications laser treatment may offer proven therapy: the Diabetic Retinopathy Study demonstrated that panretinal scatter photocoagulation reduces the risk of severe visual loss by >50% in eyes with high-risk characteristics. Panretinal scatter coagulation may also be beneficial in other PDR and severe nonproliferative diabetic retinopathy (NPDR) under certain conditions. For clinically significant macular edema the Early Treatment of Diabetic Retinopathy Study could show that immediate focal laser photocoagulation reduces the risk of moderate visual loss by at least 50%. When and how to perform laser treatment is described in detail, offering a proven treatment for many problems associated with diabetic retinopathy based on a high evidence level.

1.
Klein R, Klein BE, Moss SE: Visual impairment in diabetes. Ophthalmology 1984;91:1–9.
2.
The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968–983.
3.
The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36–51.
4.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713.
5.
Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82–106.
6.
Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1976;81:383–396.
7.
Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981;88:583–600.
8.
Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1979;97:654–655.
9.
Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report No 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987;27:239–253.
10.
Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT: Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682.
11.
Initiativgruppe Früherkennung diabetischer Augenerkrankungen (IFdA): Diagnostik, Therapie und Verlaufskontrolle der diabetischen Retinopathie und Makulopathie (Leitlinie der DDG). 2004. http://www.die-ifda.de/downloads/DDGLeitlinie2004.pdf.
12.
Initiativgruppe Früherkennung diabetischer Augenerkrankungen (IFdA): Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulopathie. 2001. http://www.die-ifda.de/html/aerzte/bildindex_aerzte.html.
13.
American Academy of Ophthalmology: Preferred practice pattern: diabetic retinopathy. 2003. http://www.aao.org/education/library/ppp/dr_new.cfm.
14.
Davies N: Altering the pattern of panretinal photocoagulation: could the visual field for driving be preserved? Eye 1999;13:531–536.
15.
Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL 3rd: Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report No 20. Arch Ophthalmol 1995;113:52–55.
16.
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:766–785.
17.
Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761–774.
18.
Ferris FL 3rd, Davis MD: Treating 20/20 eyes with diabetic macular edema. Arch Ophthalmol 1999;117:675–676.
19.
Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline – ETDRS report No. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113:1144–1155.
20.
Lewis H, Schachat AP, Haimann MH, Haller JA, Quinlan P, von Fricken MA, Fine SL, Murphy RP: Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990;97:503–510; discussion 510–501.
21.
Schatz H, Madeira D, McDonald HR, Johnson RN: Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991;109:1549–1551.
22.
Hamilton AMP, Ulbig MW, Polkinghorne P: Management of Diabetic Retinopathy. London, BMJ Publishing Group, 1996.
23.
Lee CM, Olk RJ: Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991;98:1594–1602.
24.
Ladas ID, Theodossiadis GP: Long-term effectiveness of modified grid laser photocoagulation for diffuse diabetic macular edema. Acta Ophthalmol (Copenh) 1993;71:393–397.
25.
Gandorfer A, Messmer EM, Ulbig MW, Kampik A: Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 2000;20:126–133.
26.
Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57–61.
27.
Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D: Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004;28:251–256.
28.
Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:807–822.
29.
Arend O, Wolf S, Harris A, Reim M: The relationship of macular microcirculation to visual acuity in diabetic patients. Arch Ophthalmol 1995;113:610–614.
30.
Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M: Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110:2386–2394.
31.
Benson WE, Brown GC, Tasman W, McNamara JA, Vander JF: Extracapsular cataract extraction with placement of a posterior chamber lens in patients with diabetic retinopathy. Ophthalmology 1993;100:730–738.
32.
Jaffe GJ, Burton TC, Kuhn E, Prescott A, Hartz A: Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol 1992;114:448–456.
33.
Hainsworth DP, Chen SN, Cox TA, Jaffe GJ: Condensation on polymethylmethacrylate, acrylic polymer, and silicone intraocular lenses after fluid-air exchange in rabbits. Ophthalmology 1996;103:1410–1418.
34.
Gabel VP, Birngruber R, Gunther-Koszka H, Puliafito CA: Nd:YAG laser photodisruption of hemorrhagic detachment of the internal limiting membrane. Am J Ophthalmol 1989;107:33–37.
35.
Kroll P, Busse H: Therapy of preretinal macular hemorrhages. Klin Monatsbl Augenheilkd 1986;188:610–612.
36.
Ulbig MW, Mangouritsas G, Rothbacher HH, Hamilton AM, McHugh JD: Long-term results after drainage of premacular subhyaloid hemorrhage into the vitreous with a pulsed Nd:YAG laser. Arch Ophthalmol 1998;116:1465–1469.
37.
Ulbig MW, Hamilton AM: Comparative use of diode and argon laser for panretinal photocoagulation in diabetic retinopathy. Ophthalmologe 1993;90:457–462.
38.
Bandello F, Brancato R, Trabucchi G, Lattanzio R, Malegori A: Diode versus argon-green laser panretinal photocoagulation in proliferative diabetic retinopathy: a randomized study in 44 eyes with a long follow-up time. Graefes Arch Clin Exp Ophthalmol 1993;231:491–494.
39.
Ulbig MR, Arden GB, Hamilton AM: Color contrast sensitivity and pattern electroretinographic findings after diode and argon laser photocoagulation in diabetic retinopathy. Am J Ophthalmol 1994;117:583–588.
40.
Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S: Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004;24:507–511.
41.
Akduman L, Olk RJ: Diode laser (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema. Ophthalmology 1997;104:1433–1441.
42.
Gupta V, Gupta A, Kaur R, Narang S, Dogra MR: Efficacy of various laser wavelengths in the treatment of clinically significant macular edema in diabetics. Ophthalmic Surg Lasers 2001;32:397–405.
43.
Friberg TR: Infrared micropulsed laser treatment for diabetic macular edema – subthreshold versus threshold lesions. Semin Ophthalmol 2001;16:19–24.
44.
Luttrull JK, Musch DC, Mainster MA: Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:74–80.
45.
Laursen ML, Moeller F, Sander B, Sjoelie AK: Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004;88:1173–1179.
46.
EDTRS: Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98:786–806.
47.
Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F 3rd: Detection of diabetic macular edema: ophthalmoscopy versus photography – Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology 1989;96:746–750; discussion 750–741.
48.
Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS, Izatt JA, Swanson EA, Fujimoto JG: Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995;102:217–229.
49.
Neubauer AS, Priglinger S, Ullrich S, Bechmann M, Thiel MJ, Ulbig MW, Kampik A: Comparison of foveal thickness measured with the retinal thickness analyzer and optical coherence tomography. Retina 2001;21:596–601.
50.
Neubauer AS, Priglinger S, Thiel MJ, Bechmann M, Ulbig MW: Retinal maps: Retinal thickness analyzer (RTA) compared to optical coherence tomography (OCT). IOVS Suppl 2001;42:S793.
51.
Polito A, Shah SM, Haller JA, Zimmer-Galler I, Zeimer R, Campochiaro PA, Vitale S: Comparison between retinal thickness analyzer and optical coherence tomography for assessment of foveal thickness in eyes with macular disease. Am J Ophthalmol 2002;134:240–251.
52.
Shahidi M, Ogura Y, Blair NP, Rusin MM, Zeimer R: Retinal thickness analysis for quantitative assessment of diabetic macular edema. Arch Ophthalmol 1991;109:1115–1119.
53.
Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM: Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004;122:330–335.
54.
Browning DJ, McOwen MD, Bowen RM Jr., O’Marah TL: Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 2004;111:712–715.
55.
Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montanes J, Garcia-Layana A: Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588–1594.
56.
Giovannini A, Amato GP, Mariotti C, Ripa E: Diabetic maculopathy induced by vitreo-macular traction: evaluation by optical coherence tomography (OCT). Doc Ophthalmol 1999;97:361–366.
57.
Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA: Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina 2000;20:115–120.
58.
Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A: Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003;135:169–177.
59.
Parolini B, Panozzo G, Gusson E, Pinackatt S, Bertoldo G, Rottini S, Pignatto S: Diode laser, vitrectomy and intravitreal triamcinolone: a comparative study for the treatment of diffuse non tractional diabetic macular edema. Semin Ophthalmol 2004;19:1–12.
60.
Ferris F: Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996;94:505–537.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.